Literature DB >> 32482959

Prospective Clinical Study of Keratoconus Progression in Patients Awaiting Corneal Cross-linking.

Yi Wei Goh1, Akilesh Gokul1, Mohammad E Yadegarfar2, Hans Vellara1, William Shew1, Dipika Patel1, Charles N J McGhee1, Mohammed Ziaei1.   

Abstract

PURPOSE: Keratoconus progression should be treated with corneal cross-linking (CXL) in a timely manner. This study aimed to investigate patient factors associated with keratoconus progression between time of listing and at time of CXL.
METHODS: Prospective observational study at a tertiary center. Ninety-six eyes of 96 patients with keratoconus. Demographic, clinical, and tomographic parameters were analyzed to determine the risk factors for keratoconus progression. Analyzed tomographic indices included steepest keratometry, average keratometry, cornea thinnest point, index of surface variance, index of vertical asymmetry, keratoconus index, center keratoconus index, index of height asymmetry, and index of height decentration.
RESULTS: A total of 38 eyes (39.6%) were found to have keratoconus progression during an average waiting time of 153 ± 101 days. There were significant differences in preoperative tomographic parameters such as index of surface variance (111.3 ± 36.6 vs. 88.3 ± 31.8; P = 0.002), index of vertical asymmetry (1.1 ± 0.4 vs. 0.9 ± 0.4; P = 0.005), keratoconus index (1.31 ± 0.12 vs. 1.22 ± 0.11; P < 0.001), and index of height decentration (0.16 ± 0.07 vs. 0.11 ± 0.06; P = 0.015) between eyes that progressed and those that remained stable. There were no significant differences in steepest keratometry, average keratometry, cornea thinnest point, and center keratoconus index. Multivariate analysis did not reveal age, presence of atopy/atopic keratoconjunctivitis, eye rubbing, or waiting time to be a significant risk factor for progression; however, Maori ethnicity was a risk factor (odds ratio = 3.89; P = 0.02).
CONCLUSIONS: A significant proportion of eyes were found to be progressing while waiting for CXL. A risk stratification score for patients awaiting CXL may reduce the risk of progression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32482959     DOI: 10.1097/ICO.0000000000002376

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  What are the costs, capacity, and clinical implications of 'waiting for documented progression' in young West of Scotland patients prior to collagen cross linking?

Authors:  Alasdair Simpson; Kerr Brogan; Kanna Ramaesh; David Lockington
Journal:  Eye (Lond)       Date:  2021-02-24       Impact factor: 3.775

2.  Keratoconus detection of changes using deep learning of colour-coded maps.

Authors:  Xu Chen; Jiaxin Zhao; Katja C Iselin; Davide Borroni; Davide Romano; Akilesh Gokul; Charles N J McGhee; Yitian Zhao; Mohammad-Reza Sedaghat; Hamed Momeni-Moghaddam; Mohammed Ziaei; Stephen Kaye; Vito Romano; Yalin Zheng
Journal:  BMJ Open Ophthalmol       Date:  2021-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.